Molecular Partners Ag (MOLN) Accumulated Expenses (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Accumulated Expenses of $7235.5 for Q1 2026, up 21.62% year-over-year from $5949.4 in Q1 2025, and down 28.21% quarter-over-quarter from $10078.2 in Q4 2025.
Molecular Partners Ag (MOLN) Accumulated Expenses (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Accumulated Expenses for 7 consecutive years, with $7235.5 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 21.62% year-over-year to $7235.5; the TTM figure through Mar 2026 stood at $7235.5 (up 21.62% YoY), while the FY2025 annual figure was $10078.2, down 99.89% from the prior year.
- Accumulated Expenses eased to $7235.5 in Q1 2026 per MOLN's latest filing, from $10078.2 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $8.8 million in Q4 2024 and bottomed at $5256.6 in Q1 2023.
- Historically, Accumulated Expenses has averaged $2.8 million across 5 years, with a median of $10078.2 in 2025.
- On a YoY basis, Accumulated Expenses climbed as much as 32.97% in 2025 and fell as far as 99.89% in 2025.
- Molecular Partners Ag's Accumulated Expenses stood at $7.8 million in 2022, then grew by 9.27% to $8.5 million in 2023, then gained by 3.43% to $8.8 million in 2024, then tumbled by 99.89% to $10078.2 in 2025, then retreated by 28.21% to $7235.5 in 2026.
- Business Quant data shows MOLN's Accumulated Expenses at $7235.5 in Q1 2026, $10078.2 in Q4 2025, and $10494.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,235.51 |
| Dec 31, 2025 | 10,078.17 |
| Sep 30, 2025 | 10,494.67 |
| Jun 30, 2025 | 11,721.37 |
| Mar 31, 2025 | 5,949.43 |
| Dec 31, 2024 | 8.80 Mn |
| Sep 30, 2024 | 7,892.47 |
| Jun 30, 2024 | 7.41 Mn |
| Mar 31, 2024 | 6,820.25 |
| Dec 31, 2023 | 8.51 Mn |
| Sep 30, 2023 | 7,925.07 |
| Jun 30, 2023 | 6.55 Mn |
| Mar 31, 2023 | 5,256.61 |
| Dec 31, 2022 | 7.79 Mn |
| Sep 30, 2022 | 6,699.40 |
| Jun 30, 2022 | 7.85 Mn |
| Mar 31, 2022 | 7,313.29 |
| Dec 31, 2021 | 10.82 Mn |
| Sep 30, 2021 | 9,761.86 |
| Dec 31, 2020 | 8.54 Mn |